Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. sues to block Philadelphia safe drug-injection site

The U.S. Justice Department filed a lawsuit seeking to stop a nonprofit in Philadelphia from opening what could become the nation’s first supervised drug-injection site in an effort aimed at addressing opioid abuse.

Read More »

Pain Therapeutics Criticizes FDA Following Meeting Over Thrice-Rejected Remoxy

Austin, Texas-based Pain Therapeutics Inc. announced feedback from a meeting held Jan. 31, 2019, with the U.S. Food and Drug Administration regarding the drug candidate Remoxy ER, an abuse-deterrent extended-release gel formulation of oxycodone.

Read More »

GSK Cuts Six Respiratory Assets as It Continues to Focus on Oncology Treatments

GlaxoSmithKline is significantly reshaping to focus on pharmaceuticals, particularly a renewed interest in oncology treatments. As a result, the company made some cuts to the product pipeline, including six in GSK’s 2018 year-end report.

Read More »

Eli Lilly backs U.S. proposal on drug rebates to lower costs

Eli Lilly embraced a U.S. government proposal to end a decades-old system of rebates drugmakers make to industry middlemen.

Read More »

Roche, joining rivals, donates hemophilia drug to boost access

Switzerland’s Roche will donate the company’s new hemophilia A drug Hemlibra to a World Hemophilia Federation program, joining rivals who also back the effort to help patients in developing countries who face treatment hurdles.

Read More »

With New CEO MIA, Gilead Reports Tough Q4 and 2018

Gilead Sciences reported earnings per share profits for the 2018 fourth quarter of $1.44 per share, below analysts’ expectations of $1.70. Revenue for the quarter was $5.8 billion, better than Wall Street’s $5.5 billion expectations, but down from $5.949 billion in the same quarter during 2017.

Read More »

Roche, Forma Cutting Jobs in Massachusetts

More than 100 Boston-area employees from two pharma companies are getting pink slips. Roche and Forma Therapeutics filed WARN notices with the state of Massachusetts.

Read More »

Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting

Cidara Therapeutics Inc. announced that data from studies of the biotechnology company’s lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR to be held in Houston from Feb. 20-24.

Read More »

GSK, Merck KGaA ink cancer immunotherapy deal

GlaxoSmithKline bolstered the company’s cancer drug development pipeline, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Merck KGaA for the rights to a next-generation immunotherapy.

Read More »

FreshBlood HMC Expands to Become FreshBlood Group

FreshBlood Health Market Consultants, which was launched in 2015 by prominent healthcare industry marketing expert Robert Finkel, announced the life-science solutions provider’s expanded creative services capabilities and official reconfiguration as FreshBlood Group.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom